Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies

Abstract

Regenerative medicine therapies hold enormous potential for a variety of currently incurable conditions with high unmet clinical need. Most progress in this field to date has been achieved with cell-based regenerative medicine therapies, with over a thousand clinical trials performed up to 2015. However, lack of adequate safety and efficacy data is currently limiting wider uptake of these therapies. To facilitate clinical translation, non-invasive in vivo imaging technologies that enable careful evaluation and characterisation of the administered cells and their effects on host tissues are critically required to evaluate their safety and efficacy in relevant preclinical models. This article reviews the most common imaging technologies available and how they can be applied to regenerative medicine research. We cover details of how each technology works, which cell labels are most appropriate for different applications, and the value of multi-modal imaging approaches to gain a comprehensive understanding of the responses to cell therapy in vivo.

Introduction

Cell-based regenerative medicine therapies (RMTs) and their translation to clinical application are now a major focus of research and are likely to play a key role in future clinical practice. Broadly, cell-based RMTs encompass various cell types, including stem cells, stromal cells, and macrophages and have the potential to treat many diseases, including neurodegenerative and musculoskeletal disorders.1 Many RMTs have shown great promise in preclinical studies for various diseases, including kidney2 and liver diseases,3 type I diabetes and myocardial infarction4; however, success in the clinical setting is limited, with only a small panel of fully approved RMTs available to patients, such as dermal reconstruction, or repair of orthopaedic defects.5 The slow translation of RMTs from bench to bedside is primarily due to the lack of convincing data on the safety of RMTs, in addition to uncertainties on the true efficacy and mode of action of the cell therapy.6 The importance of acquiring convincing safety and efficacy data in preclinical models before applying such therapies in man is underscored by the disastrous outcomes of bioengineered tracheal transplantation, a procedure that was applied in man before being shown to be safe or effective in animals.7 Commercial stem-cell clinics around the world can now use autologous cellular therapies outside the experimental clinical trial settings endangering patient’s health.8 A clear example happened in three patients in the US whom clinically received intravitreal injections of autologous adipose tissue-derived “stem cells” and developed severe bilateral visual loss.9

The main concerns regarding translation of cell-based RMTs to the clinic are:

  1. 1.

    Tumourigenicity—Pluripotent stem cell-based RMTs are a particular concern due to the propensity of these cells to from teratomas and/or teratocarcinomas; it is important for the tumourigenicity of these cell-based RMTs to be assessed in animal models before being used in the clinic.

  2. 2.

    Immunogenicity—RMTs consisting of allogeneic cells have the potential for evoking an immune reaction in the host; this needs to be managed with respect to the function of the therapy before the RMT is translated to the clinic.

  3. 3.

    Efficacy—The RMT must be proven to have greater efficacy compared to standard therapies for treating a particular disease.

  4. 4.

    Mechanisms of action—It is important to fully understand why the RMT is having a beneficial effect in order to understand whether the cells themselves are therapeutic, or their derived factors.

  5. 5.

    Risk:Benefit ratio—All of the above points need to be considered with the risk:benefit ratio in mind. For example, a small risk of tumourigenicity is likely to be more acceptable if it is being used to treat a life-threatening disease with no alternative treatment (high benefit), than if the RMT is being used to treat a condition that is not life-limiting and/or only provides a modest advantage over current treatments (low benefit).

Relevant animal models, where available, are essential to gain a better understanding of both the efficacy and the safety of cell-based RMTs. Current methods generally rely on histological analysis of tissues post-mortem.10 This approach requires many experimental animals to be sacrificed at multiple time points in order to gain a comprehensive insight into in vivo processes following administration of the RMT. Importantly, it does not allow researchers to monitor individual animals over the course of their treatment. This need can be addressed by developing non-invasive imaging methods that can monitor the response of each animal longitudinally.11

Preclinical imaging encompasses several different imaging modalities, some of which are only suitable for imaging small animals, and others that can be used in large animals and in the clinic.12 Modalities which can be universally applied include magnetic resonance imaging (MRI) and nuclear imaging. Other modalities, such as optical and whole-body optoacoustic imaging, can only be used in small animals, but are nevertheless invaluable because they allow the whole-body biodistribution of the cells to be monitored over the long-term using genetic reporters; this is not currently possible in the clinical setting.

We aim to provide a review of preclinical imaging with a particular focus on assessing the safety, efficacy, and mechanisms of action of RMTs. There are several different imaging modalities available in preclinical research, but this review will focus on the four main modalities, which are: optical (fluorescence and bioluminescence imaging (FLI; BLI)), MRI, nuclear imaging, and optoacoustic imaging.

Preclinical imaging and cell labelling

Imaging modalities

Optical imaging is a commonly used modality, as it can provide fast, high-throughput, whole-body imaging13 (see Box 1, Table 1). Transplanted cells containing fluorescence or (bio)luminescence, either as a result of directly labelling the cells with probes (see Box 2) or by introducing reporter genes (see Box 3), can be tracked using optical imaging, thus allowing the monitoring of cell biodistribution and tumour formation. Disadvantages of optical imaging include low penetration depth, poor spatial resolution, and poor quantification capabilities.13

Table 1 Summary of the features of the four most commonly used imaging modalities in preclinical research

MRI provides excellent anatomical information with unlimited tissue penetration depth14 (see Box 1, Table 1), allowing detailed structural examination of organs before and after RMT administration. Additionally, cells labelled with paramagnetic or superparamagnetic agents (see Box 2) or over-expressing magnetic resonance (MR) reporter genes such as ferritin, tyrosinase, or β-galactosidase (see Box 3) can be tracked using MRI, although most MR reporters have been shown to have limited efficacy.15 The detailed structural information obtained from MR images allows the biodistribution of labelled cells to be attributed to specific organs with far greater accuracy and spatial resolution than with optical imaging. However, it is difficult to track cells in regions with inherently variable MRI contrast, such as the lungs, bone, gut, and spleen.16 Because cell tracking via MR is dependent on the effect the labelling agent has on water proton signal (T1/T2 relaxation), the observed contrast is not always easily discriminated from other pathological processes. For example, labelling with iron oxides reduces T2/T2 * signal, an effect that is also seen in areas of haemorrhage or in iron overload diseases such as hemosiderosis. Unlike iron oxides, gadolinium chelates give a positive T1 signal but at a lower sensitivity and greater likelihood of cell toxicity, making it less suitable for biodistribution studies. None of these MR methods can be directly correlated with cell number and thus provide no quantifiable metrics of cell distribution. Perfluorocarbons yield signal that originates unequivocally from the labels and that can be quantitated and directly correlated to the number of cells in the tissue, but requires specialised coils and still suffers from a relatively low sensitivity, particularly at clinical field strengths.17

Nuclear imaging makes use of radioactive probes to produce images of physiological or functional significance from within the body.18, 19 There are two major nuclear imaging modalities used in both preclinical and clinical practice: PET and SPECT. Cells directly labelled with radionuclides such as Indium-111 (111In), Zirconium-89 (89Zr), and Technetium-99m (99mTc) (see Box 2) or transduced with nuclear reporter genes (see Box 3) can be tracked with very high sensitivity; however the application of nuclear imaging is limited due to the use of short-lived radioisotopes, and the potential negative effects on the health of the therapeutic cells.20

Optoacoustic imaging is a relatively new imaging modality which has become more commonly used in recent years. Optoacoustic imaging relies on strong light absorbers, which can be endogenous or exogenous molecules or probes (see Box 1, Table 1). Endogenous biological contrasts include oxy-haemoglobin and deoxy-haemoglobin, melanin, water, and lipids,21 and are valuable for imaging vasculature, oxygenation status, and tumours.22 However, it is the use of exogenous contrast that is of particular interest to RMT applications. A commercially available optoacoustic imager called ‘multispectral optoacoustic tomography’ (MSOT) is capable of imaging at multiple wavelengths.23 By detecting acoustic waves, MSOT is able to overcome the scattering of emitted light which usually limits the detection depth of many optical imaging methods, thus permitting imaging depths of several centimetres, and allowing the whole-body imaging of a mouse.24 Importantly, by illuminating tissues at multiple wavelengths, the signals from different absorbers can be spectrally unmixed, allowing the differential identification of multiple absorbers at once. For cell tracking purposes, cells can be labelled with probes that absorb within the near-infrared (NIR), such as gold nanorods25 or carbon nanotubes (see Box 2), or can be labelled with reporter genes encoding NIR fluorescent proteins (see Box 3). Moreover, optoacoustic imaging can be performed in real time, allowing quantitative assessment of organ function,26 thus enabling efficacy studies in addition to cell tracking. Even though this imaging technology is relatively new it has recently been clinically used in oncology,27 human vasculature28 and inflammatory response.29

Cell labelling

As indicated above, there are two broad categories of cell labels: labelling probes and reporter genes. Labelling probes, also known as direct labels, are required to be taken up by the cells (see Box 2, Fig. 1), whereas the use of reporter genes requires genetic modification of the cells (see Box 3, Fig. 1).

Fig. 1
figure1

Diagram of the two classes of cell labelling methods, labelling probes and reporter genes, and examples of the labels used for each. a Labelling cells with probes involves the uptake of exogenous probes e.g. SPION, 111In-oxine, QD, GNR, directly in to the cytoplasm of cells. b Reporter gene labelling requires the introduction of foreign DNA into the cell’s DNA, to express a reporter protein. The reporter protein either generates signal using endogenous substrates (e.g., ferritin), or it interacts with an exogenous substrate/detectable probe (e.g., luciferase, HSV1-tk, human sodium iodide symporter (hNIS))

Probes used for cell labelling can produce a very strong signal due to high cellular uptake30; however, they suffer from the disadvantage that, when imaging, it is the probe, and not the cell itself, which is being imaged.31 This presents a problem for false positive results in cell tracking if the probe is released from the cell of interest and taken up by host cells.32 Moreover, when cells labelled with probes divide, the probes within the cell are distributed between the daughter cells, resulting in signal dilution.31 Therefore, when monitoring tumour growth, the probe can no longer be detected following several cell divisions.

With the exception of luciferase enzymes, reporter genes (e.g., MR and optoacoustic reporters) tend to produce weaker signals than imaging probes,33 with the limiting factors including substrate biodistribution, background uptake and clearance, and/or the expression levels of the reporter gene that can be achieved in a given cell type.34 Moreover, some reporter genes, such as the nuclear reporter gene HSV1-tk can generate an immune response in the host, thus limiting the potential for long-term imaging.35 The advantage of reporter genes, however, is that the genetic modification required to label the cells is passed onto daughter cells during cell division, so that the signal intensity increases as the cells proliferate, and signals are only lost when the cells die.36

The ideal cell tracking agent should:

  1. (I)

    be non-toxic to the cell and should not change the cell’s phenotype, function, or differentiation potential;

  2. (II)

    be easily taken up by the cell and should remain in the desired location, either intracellular or membrane-bound;

  3. (III)

    emit a strong signal for easy detection following administration;

  4. (IV)

    allow for quantification of cell number;

  5. (V)

    enable live and dead cells to be distinguished;

  6. (VI)

    permit the identification of the cell’s metabolic and differentiation status. However, this is challenging and so far has only been achieved using reporter genes under the control of cell-specific promoters.37

If using fluorescence or optoacoustic imaging, the label should absorb light maximally within the NIR wavelength range (see Box 4), as it is within this range that the absorption of endogenous pigments, such as haemoglobin, melanin and fat are at a minimum. This allows light to penetrate deeper into the tissue, and signals from cell labels can be detected from deeper within the animal’s body.

Fig. 2
figure2

The absorption coefficients of the main tissue absorbers, water and oxy- and deoxy-haemoglobin, over 600–1100 nm. The absorption of these endogenous pigments is at its lowest from 700–900 nm, creating an ‘optical window’ for in vivo imaging. Reprinted with permission from Macmillan Publishers Ltd: Phan, T. G. and Bullen, A. Practical intravital two-photon microscopy for immunological research: faster, brighter, deeper. Immunology and Cell Biology 88, 438–444, doi:10.1038/icb.2009.116 (2014)

Preclinical imaging approaches to evaluate cell-based RMTs

Cell biodistribution

It is essential to be able to track cells following their administration and engraftment into the host, and imaging methods can be used to answer some key questions regarding cell biodistribution. For example, where do the cells go when they are administered, particularly if they are administered systemically? Following systemic injection, do the cells eventually reach the target organ, and how long does it take them to do so? Do the cells integrate within non-target organs? Alternatively, if the cells are administered directly to the target organ, was the injection successful? Do the cells stay within the target organ, or do they migrate elsewhere over time?

Previously, these questions would have been answered by sacrificing multiple animals at several different time points and detecting the transplanted cells via histological techniques. However, by using imaging modalities, labelled cells can be tracked over time in individual animals.38 Bioluminescence imaging is one of the most useful modalities for monitoring cell biodistribution, as whole body images of multiple animals can be generated simultaneously in a matter of seconds, while detecting as few as 10 cells.39 This modality can be used to monitor the immediate biodistribution of cells following administration, and is particularly useful for confirming a successful injection,40 in addition to tracking cell biodistribution over time (Fig. 2). Most importantly, due to the requirement of an active ATP metabolism for light production in cells expressing firefly luciferase, this reporter provides a remote and highly-sensitive readout on whether the cells are alive or not. Using bioluminescence imaging, Yi Tang et al. tracked luciferase+ neural progenitor cells for up to 4 weeks as they migrated through the parenchyma of the brain from the injection site into a brain tumour.38 However, a limit to optical imaging is its depth limitation and poor spatial resolution13 and the fact that it is mostly restricted to 2D planar imaging. This means that although the general biodistribution of cells can be imaged, it can be difficult to tell exactly which organ the cells are located in, and it is not possible to monitor distribution within specific organs. 3D optical imaging is possible,41 but it relies on a pre-determined anatomical template, which may not accurately match with the individual animal.

Fig. 3
figure3

PET imaging shows the three dimensional biodistribution of intravenously injected human adipose-derived stem cells labelled with 89Zr-oxine. Bioluminescence imaging confirms their viability and the co-location of the cells and the radiotracer. Data generated at the Centre for Advanced Biomedical Imaging (CABI), University College London

MRI and optoacoustic imaging are both able to provide much higher spatial resolution,42, 43 and so can provide more detailed information regarding cell location, and in some cases can also allow for quantification of approximate cell number. Nam et al. used ultrasound-guided optoacoustic imaging to track mesenchymal stem cells (MSC) labelled with gold nanotracers for 1 week following implantation.44 In vitro studies from this group suggested that the amplitude of the optoacoustic signal was directly related to the concentration of gold nanotracers, allowing for reasonable confidence in the quantification of cell numbers in vivo.44

Nuclear imaging, e.g., PET and SPECT, are highly sensitive imaging modalities that can be used to track cell biodistribution in vivo over the short-term and long-term, based on radionuclide probe or genetic reporters, respectively. The PET probe, [18F]-2-fluoro-2-deoxy-d-glucose (18F-FDG), is a widely used biomarker of cancer because it measures glucose metabolism, which is increased in cancer cells. 18F-FDG can also be used to monitor the immediate biodistribution of injected stem cells,45 but long-term tracking with 18F-FDG is not possible due to its short half-life (110 min). Cells can be tracked for up to a few days using isotopes with longer half-lives, such as copper-64 (64Cu), 111In, and 89Zr,46, 47 but longer-term tracking requires the use of genetic reporters, such as the HSVtk reporter that has been used to monitor the biodistribution of progenitor cells for over 5 months in a porcine model of myocardial injury.48 HSV1-tk has been the most widely used nuclear reporter system to have been used in a range of regenerative cell types in vivo,48 it is the only reporter gene to have been clinically translated for the purpose of monitoring T cell immunotherapies to cancer.49 As previously mentioned, immunogenicity of a non-human derived reporter protein has been a problem for clinical translation. To overcome this limitation, a human mitochondrial thymidine kinase type 2 (hTK2) has been proposed.50 The further development of nuclear reporter systems for regenerative cells has therefore been based on human derived genes that have been previously worked up in other cell lines, such as the as the D2R,51 and NIS52 systems. Although this counters any immunogenicity concerns, the limitation is that there is increased background uptake of the reporter probe natively expressing tissues within the body. The sensitivity and resolution is thereby dependent on the biodistribution of the reporter probe. A shorter half-life is preferred for radionucleotide probes for reporter systems as this allows for multiple imaging acquisitions over a longitudinal time frame such as in the case of the HSVtk reporter which has been used to monitor the biodistribution of progenitor cells for over 5 months in a porcine model of myocardial injury. Alternative approaches that involve the systemic administration of cell targeting probes can also be used to monitor cell biodistribution and/or provide information on cell phenotype. For example, 64Cu (bound to arginine-glycine-aspartic (RGD) tetramer conjugated with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA)) was used to target αvβ3 integrin, in order to detect whether human embryonic stem cells53 formed teratomas. However, a downside to this approach is the lack of specificity.

Dual-labelling of cells with both probes for short-term tracking and reporter genes for long-term tracking might satisfy requirements for both highly sensitive immediate biodistribution, as well as longitudinal tracking for tumour monitoring. For example, cells could be transduced with luciferase for bioluminescence imaging, providing high sensitivity but poor spatial resolution, and also labelled with SPIONs for MR imaging, permitting the intra-organ biodistribution to be evaluated with the excellent spatial resolution of MRI (Fig. 5).

Alternatively, cells could be labelled with a single reporter gene which allows for dual-modal imaging. Patrick et al. described a reporter gene system based on the organic anion transporting protein (Oatp1a1), which mediated the uptake of two contrast agents for MRI and SPECT imaging, gadolinium- (Gd) ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-DTPA) and 111In-EOB-DTPA, respectively.54 Oatp1a1-expressing cells were implanted in the flanks of mice, and after systemic administration of contrast agent, could be imaged longitudinally using both MRI and SPECT, thus combining the advantages of both modalities: i.e., the high spatial resolution of MRI, and the sensitivity of SPECT. Further, their sensitivity of detection with bioluminescence was enhanced, due to Oatp1a1’s ability to increase uptake of the substrate.55 Unlike labelling probes such as SPIONs or radionuclides used to track cells with MRI and SPECT, this reporter gene system can be used to monitor dividing cells over time, and does not suffer from signal dilution.

Ngen et al. have described a dual contrast system comprised of SPIONs and gadolinium chelates, which generate opposing contrast signals and allow for the differentiation between live and dead cells.56 When both contrast agents are present in live cells, the strong T2 signal from the SPIONs quenches the T1 contrast from the gadolinium chelates. However, when cells die, the gadolinium chelates are released and diffuse away from the SPIONs, allowing the T1 signal to be detected in the region surrounding the dead cells.56

When aiming to track cells over a long period, the cell label should be chosen carefully. Some cell labels, while very sensitive, cannot be detected after a certain period, due to either their chemical degradation or radioactive decay. As a general rule, labelling probes are unsuitable for long-term cell tracking, unless the cells are non-proliferating; for instance, it has previously been shown that SPION-labelled neural progenitor cells can be tracked in vivo for several weeks with MRI as these cells do not proliferate following their differentiation.57

Tumourigenicity

A well-known safety concern of cell-based RMTs is the potential for tumour formation by the engrafted cells.42 Stem cells have the capacity for self-renewal and as such, may proliferate after administration to form tumours.58 Pluripotent stem cells (PSCs) pose a particular risk due to their tendency to form teratomas and/or teratocarcinomas. However, with PSC-based therapies, it is not the undifferentiated PSCs themselves that are administered, but rather, their more differentiated derivatives; for instance, PSC-derived retinal pigment epithelial cells are currently being tested in the clinic for their potential to treat age-related macular degeneration (ARMD).59 The main concern with such therapies is the risk of tumour formation in the host by small numbers of contaminating undifferentiated PSCs which might be present within the administered population.

As it is difficult to completely exclude this possibility, even when using sensitive techniques such as quantitative PCR, it is important to assess the risk of tumourigenicity in animal models prior to commencing clinical trials. This is most easily done using constitutively expressed reporter genes, because if integrated into the genome, the reporter genes will be passed onto the daughter cells when the original cells divide.36 Thus, if the cells proliferate following transplantation, there will be an increase in signal intensity, enabling tumour growth to be monitored in vivo36 (Fig. 6).

Fig. 4
figure4

The absorption coefficients of the main tissue absorbers, water and oxy-haemoglobin and deoxy-haemoglobin, over 600–1100 nm. The absorption of these endogenous pigments is at its lowest from 700–900 nm, creating an ‘optical window’ for in vivo imaging. Reprinted with permission from Macmillan Publishers Ltd: Phan, T. G. and Bullen, A. Practical intravital two-photon microscopy for immunological research: faster, brighter, deeper. Immunology and Cell Biology 88, 438–444, doi:10.1038/icb.2009.116 (2014)

In addition to the administered cells themselves forming tumours, it is also possible that they could promote the growth of endogenous tumours that are already present in the host; this has previously been demonstrated following the administration of MSCs into immune-compromised mice.60 Sensitive techniques are required to detect such tumours, the most common being 18F-FDG-PET, which can be used in both the preclinical and clinical setting. Various approaches based on optoacoustic imaging are also being developed, including enhanced haemoglobin contrast that is a feature of highly vascularised tumours61 and uptake of the NIR dye, indocyanine green, which passively accumulates in tumours.62 Furthermore, specific tumour imaging can be achieved by conjugating optoacoustic probes such as gold nanoparticles to antibodies specific to particular cancer cell antigens.63

Immunogenicity

Cell-based RMTs derived from allogeneic sources have a high risk of being immunogenic.64 Even autologous cells derived from the patient have the potential to evoke an immune reaction when transplanted back into the host, as in vitro culture conditions may induce genetic, epigenetic, and phenotypic changes within the cells.62,65 Prior to translating a cell therapy to the clinic, it is important to try to determine the immunogenic potential of the human cells as thoroughly as possible. This cannot be done using animal models alone due to the inherent differences between animal and human immune systems,61 and a combination of in vitro and in vivo studies is required. Nevertheless, adoptive transfer and subsequent imaging of immune cells may provide a means by which to monitor an animal’s immune response to cell therapy over time.

A fluorescent lipophilic dye, 1,1-dioctadecyltetramethyl indotricarbocyanine iodide (DiR), has been used previously to label and track adoptively transferred macrophages66 and T-lymphocytes,67 thus allowing imaging of the immune reaction by proxy of exogenously administered cells. Eisenblätter et al. administered DiR-labelled macrophages intravenously to a mouse model of cutaneous granuloma, to non-invasively monitor the early inflammatory response to subcutaneously implanted lipopolysaccharide.66 This approach could be applied to image the inflammatory response following the administration of an RMT. Further, a range of fluorescent probes can be directly administered to animals to image sites of inflammation using fluorescence imaging.68 Haney et al. used the XenoLight RediJect Chemiluminescent Probe, by Perkin Elmer, to image inflammation levels following macrophage-mediated therapeutic drug delivery in a mouse model of Parkinson’s disease.68 Alternatively, Faraj et al. recently used MRI to non-invasively track SPION-labelled macrophages to sites of inflammation in a mouse model of chronic obstructive pulmonary disorder.69

Optoacoustic imaging can also be used to monitor the immune response to administered cells. Ricles et al. labelled cells with both gold nanorods and gold nanospheres, which have different absorption spectra, thus allowing the two labels to be distinguished separately in vivo.70 The peak absorption of gold nanospheres is changed when they are endocytosed by macrophages, allowing the differential identification of signals coming from live cells labelled with gold nanorods, and those coming from endocytosed cells labelled with the now-visible gold nanospheres. Using this method, Ricles et al. could monitor the viability of administered therapeutic cells in vivo and the rate of tissue macrophage infiltration over time. Additionally, by conjugating gold nanorods to antibodies for inflammatory cytokines, inflammation can be detected in vivo using optoacoustic imaging.71

However, for many reasons, we may not be able to fully understand the immunogenic potential of cell therapies during preclinical testing. Many products in preclinical research are xenogeneic in the animal model, and differences in the animal and human cellular product mean that the animal equivalent is not fully predictive of the potential for immunogenicity in humans. Moreover, for preclinical testing of a xenogeneic product, the animals will either be immunocompromised or suppressed, which is not necessarily the case in the clinical setting. Nonetheless, preclinical imaging can aid in understanding aspects of the interaction of the therapy with the immune system, and may be able to inform the selection of RMTs with a lower potential for immunogenicity.

Monitoring cell fate

An important aspect of monitoring the safety and efficacy of RMTs involves understanding the fate of the cells following administration. This is especially important for therapies based on progenitor cells, where amelioration of disease requires the cells to differentiate in vivo to one or more specialised cell types; examples of such therapies include pluripotent stem cell (PSC)-derived dopaminergic neuroblasts and PSC-derived oligodendrocyte precursor cells for the treatment of Parkinson’s disease72 and multiple sclerosis,73 respectively. Differentiation status can be assessed using cell-type-specific promoters to drive the expression of a reporter gene. By combining a cell type-specific reporter with a constitutively expressed reporter, it would be possible to monitor the viability and biodistribution of all cells within the administered population, and determine the proportion of cells which undergo differentiation.

Recently, Ahn et al. demonstrated the use of a dual reporter gene encoding both renilla and firefly luciferases, which can be imaged independently using bioluminescence imaging.74 In stably-transduced embryonic stem cells, the expression of renilla luciferase was driven by the Oct4 promoter, and the expression of firefly luciferase was driven by the ubiquitin promoter, allowing the non-invasive monitoring of stem cell differentiation in vivo.74

Imaging can be a vital tool for monitoring the effect of interventions to enhance the survival of administered cells in vivo. Yang et al. used bioluminescence imaging to assess the survival of adipose-derived stem cells (ADSCs) injected along the infarct border in a rat model of myocardial infarction.75 Some rats were administered ADSCs alone, while others were administered ADSCs in combination with an injectable fibrin scaffold to aid cell survival. BLI at 4 weeks after cell transplantation showed that the addition of the fibrin scaffold significantly improved the survival of transplanted cells.75 3D biodegradable scaffolds are very important in some RMTs, as they provide the therapeutic cells with the structural support to proliferate and differentiate appropriately. The scaffold is usually designed to break down after a certain period of time, and it is important to be able to monitor the fate of the scaffold over time. Nam et al. recently demonstrated the use of multimodal imaging for monitoring and quantifying the degradation process, in addition to monitoring the labelled therapeutic cells that were seeded on the scaffold.76

Efficacy of RMTs

In addition to monitoring cell biodistribution and fate, in vivo imaging technologies allow the assessment of organ function, and can therefore be used to monitor the efficacy of RMTs. By imaging organ function at baseline, after induction of injury, and after therapeutic intervention, it is possible to monitor each individual animal’s response to therapy. For instance, optoacoustic imaging is excellent for monitoring organ function. The clearance of exogenously administered dyes such as ICG and IRDye800 CW, which are specifically cleared through the liver26 and kidney77 (Fig. 7) respectively, allow assessment of organ function. Optoacoustic imaging can also be used to assess oxygenation status,78 brain function, such as resting state functional connectivity,79 and angiogenesis.80

Fig. 5
figure5

Multi-modal imaging of Luciferase+/SPION+ stem cells administered to the left cardiac ventricle. a BLI gives a fast confirmation of successful IC injection, and gives an approximate location of cells, but lacks organ-specific information. b MR imaging of the kidneys before and after the administration of SPION-labelled stem cells reveals that SPION-labelled cells are within the cortex of the kidney. Data generated at the Centre for Preclinical Imaging, University of Liverpool

Fig. 6
figure6

BLI of Luciferase+ mouse kidney stem cells after intracardiac administration. BLI highlights the need for longitudinal imaging, as the signal from cells can decrease initially as cells die, but tumours (arrows) may form at later time points. Data generated at the Centre for Preclinical Imaging, University of Liverpool

Fig. 7
figure7

Photoacoustic (multispectral optoacoustic tomography, MSOT) imaging of kidney clearance kinetics. a Temporal colour map indicates the time it takes for a near infrared dye to clear through different regions of the kidney; cortex (C) and pelvis/papilla (P). b Quantification of the clearance kinetics of a NIR dye through the kidneys of control mice (CTRL) and mice with kidney injury (ADR), demonstrating that photoacoustic imaging can be used to measure organ function. Reprinted under the Creative Commons CC-BY license from Scarfe et al. Scientific Reports 5, doi: 10.1038/srep13601 (2015)

Experimental imaging studies can be designed to perform cell tracking and efficacy assessment in the same animal, and during the same imaging session. Thus, individual responses to therapy can be correlated with cell biodistribution and other cell tracking data, such as proliferation and differentiation status, increasing the amount of information gained from each animal. Recently, Nam et al. demonstrated the value of optoacoustic imaging in regenerative medicine to assess the severity of injury in a cutaneous burn model, while simultaneously tracking gold nanorod-labelled ADSCs.81

MRI can also be used to image organ function and tissue regeneration. For example, Freeman et al. used MRI to assess the efficacy of MSCs administered directly into the intervertebral disc in a study of degenerative disc disease in sheep.82 Using MRI, the authors measured disc height and disc degeneration at multiple time points, allowing the response to therapy for each individual animal to be monitored over time. It is important to note that apart from anatomical imaging, MRI offers a range of advanced techniques that are currently used pre-clinically and clinically for the evaluation of disease progression and response to therapies. Those include, for example, diffusion weighted imaging, perfusion imaging and MR spectroscopy, all of which are now well established or under consideration for monitoring diseases of the heart,83 liver,84 kidney 85 and brain86 and cartilage,87 among others. Given the importance of these techniques, it is expected that many of them will be also applied for the assessing RMT efficacy.

Mechanisms of action

It is not enough simply to know that a cell type is efficacious in treating a disease. Before clinical translation, it is important to understand why the therapy appears to work, and its mechanism of action. Do the cells need to integrate within the organ of interest in order to have an effect? Do the cells even need to be present in the organ of interest, or do they have endocrine or paracrine effects which result in a resolution of the disease? If cell-derived factors rather than the cells themselves are responsible for promoting regeneration, then these could potentially be isolated and used to develop a cell-free therapy.

For instance, recent studies have shown that following intravenous injection of MSCs88 or kidney-derived cells89 into rodents with kidney disease, significant therapeutic effects were observed despite the fact that the cells were entrapped in the lung and did not engraft in the kidney. Imaging can also be used to optimise the ideal dosing conditions for maximum efficacy of a cell therapy, including the route of administration, number of cells required per dose, and timing of dosing.40, 90

As released in guidelines from the European Medicines Agency, the mechanism of action is also important to define a “potency assay”, which should be used at the release of the finished product before clinical application to show that the biological product will be able to perform the intended clinical effect. This potency assay should not only show that the cells are viable and can be identified as e.g., MSCs, but also include a functional assay. The assay demonstrating the biological activity should be based on the intended biological effect which should ideally be related to the clinical response.91

Summary

Preclinical imaging is a valuable tool for the assessment of various aspects of the safety and efficacy of RMTs prior to clinical translation. However, effective use of imaging technologies and cell labels requires full understanding of their limitations, as well as their potential. An important weakness to consider is the limit of detection, with particular emphasis on the number of cells that can realistically be detected with each modality/cell label combination. The key to successful use of imaging technologies is understanding what is achievable and what is not, and full acknowledgement of these limitations will enable the data that is generated to be put into clinical context. This will allow the consideration of subsequent alternative methods, such as traditional pathology assessment of the animals, or combination with alternative, complementary imaging technologies.

Multimodal imaging is central to effective evaluation of RMT safety and efficacy. No single imaging modality is ideal; all are associated with their own intrinsic strengths and weaknesses and by combining two or more modalities, they can complement one another to provide the maximum amount of information from a single animal. Key to this is therefore dual- or triple-labelling of the cells of interest for their visualisation by multiple imaging modalities, thus gaining more information from each animal than could be achieved with a single imaging modality.54, 56, 70 It is, however, essential that adequate in vitro analyses are performed prior to in vivo application, to ensure that all cell labels are complementary with one another, and do not have adverse effects on cell health or phenotype. Multimodal imaging approaches to monitor cell biodistribution, cell fate, therapeutic response etc., can vastly reduce the number of animals required for RMT safety and efficacy studies, as several different parameters can be assessed longitudinally in the same group of animals, without the need to sacrifice multiple animals at various time points. Multimodal imaging therefore supports the principles of the 3Rs (Reduction, Refinement, Replacement) by reducing the total number of animals required for such studies. Imaging technologies are essential in the comprehension of the mechanisms of action and potential safety issues of RMT and thus will allow a more accurate evaluation of the risk:benefit ratio of these therapies. These technologies will be essential (or a key player) to move the RMT to clinical development.

References

  1. 1.

    Mason, C. & Manzotti, E. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen. Med. 5, 307–313 (2010).

    PubMed  Article  Google Scholar 

  2. 2.

    Murray, P. A. & Woolf, A. S. Using stem and progenitor cells to recapitulate kidney development and restore renal function. Curr. Opin. Organ Transplant. 19, 140–144 (2014).

    PubMed  Article  Google Scholar 

  3. 3.

    Hannoun, Z., Steichen, C., Dianat, N., Weber, A. & Dubart-Kupperschmitt, A. The potential of induced pluripotent stem cell derived hepatocytes. J. Hepatol. 65, 182–199 (2016).

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Kemp, P. History of regenerative medicine: looking backwards to move forwards. Regen. Med. 1, 653–669 (2006).

    PubMed  Article  Google Scholar 

  5. 5.

    Davies, B. M. et al. Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: a pilot study. J. Tissue Eng. 5, 2041731414551764 (2014).

    PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Nerem, R. M. Regenerative medicine: the emergence of an industry. J. R. Soc. Interface 7, S771–775 (2010).

    PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Delaere, P. & Van Raemdonck, D. Tracheal replacement. J. Thorac. Dis. 8, S186–196 (2016).

    PubMed  PubMed Central  Google Scholar 

  8. 8.

    Daley, G. Q. Polar extremes in the clinical use of stem cells. N. Engl. J. Med. 376, 1075–1077 (2017).

    PubMed  Article  Google Scholar 

  9. 9.

    Kuriyan, A. E. et al. Vision loss after intravitreal injection of autologous “Stem Cells” for AMD. N. Engl. J. Med. 376, 1047–1053 (2017).

    PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Geburek, F. et al. Tracking of autologous adipose tissue-derived mesenchymal stromal cells with in vivo magnetic resonance imaging and histology after intralesional treatment of artificial equine tendon lesions - a pilot study. Stem Cell Res. Ther. 7, 21 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  11. 11.

    Nguyen, P. K., Riegler, J. & Wu, J. C. Stem cell imaging: from bench to bedside. Cell Stem Cell 14, 431–444 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Naumova, A. V., Modo, M., Moore, A., Murry, C. E. & Frank, J. A. Clinical imaging in regenerative medicine. Nat. Biotech. 32, 804–818 (2014).

    CAS  Article  Google Scholar 

  13. 13.

    Kim, J. E., Kalimuthu, S. & Ahn, B. C. In vivo cell tracking with bioluminescence imaging. Nucl. Med. Mol. Imaging 49, 3–10 (2015).

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Cohen, Y. & Shoushan, S. Y. Magnetic nanoparticles-based diagnostics and theranostics. Curr. Opin. Biotechnol. 24, 672–681 (2013).

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Pereira, S. M. et al. Evaluating the effectiveness of transferrin receptor-1 (TfR1) as a magnetic resonance reporter gene. Contrast Media Mol. Imaging 11, 236–244 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Vullo, A. et al. Post-mortem magnetic resonance foetal imaging: a study of morphological correlation with conventional autopsy and histopathological findings. Radiol. Med. doi:10.1007/s11547-016-0672-z (2016).

  17. 17.

    Ahrens, E. T. & Zhong, J. In vivo MRI cell tracking using perfluorocarbon probes and fluorine-19 detection. NMR Biomed. 26, 860–871 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Vrachimis, A., Honold, L., Faust, A., Hermann, S. & Schafers, M. New molecular probes of vascular inflammation. Q. J. Nucl. Med. Mol. Imaging 60, 194–204 (2016).

    PubMed  Google Scholar 

  19. 19.

    Wang, X., Feng, H., Zhao, S., Xu, J., Wu, X., Cui, J., Zhang, Y., Qin, Y., Liu, Z., Gao, T., Gao, Y. & Zeng, W. SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic. Oncotarget 12, 20476–20495 (2017).

    Google Scholar 

  20. 20.

    Gholamrezanezhad, A. et al. Cytotoxicity of 111In-oxine on mesenchymal stem cells: a time-dependent adverse effect. Nucl. Med. Commun. 30, 210–216 (2009).

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Yao, J. & Wang, L. V. Photoacoustic tomography: Fundamentals, advances and prospects. Contrast Media Mol. Imaging 6, 332–345 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Ermolayev, V., Dean-Ben, X. L., Mandal, S., Ntziachristos, V. & Razansky, D. Simultaneous visualization of tumour oxygenation, neovascularization and contrast agent perfusion by real-time three-dimensional optoacoustic tomography. Eur. Radiol. 26, 1843–1851 (2016).

    PubMed  Article  Google Scholar 

  23. 23.

    Ma, R., Taruttis, A., Ntziachristos, V. & Razansky, D. Multispectral optoacoustic tomography (MSOT) scanner for whole-body small animal imaging. Opt. Express 17, 21414–21426 (2009).

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Razansky, D. et al. Multispectral opto-acoustic tomography of deep-seated fluorescent proteins in vivo. Nat. Photon. 3, 412–417 (2009).

    CAS  Article  Google Scholar 

  25. 25.

    Comenge, J. et al. Preventing plasmon coupling between gold nanorods improves the sensitivity of photoacoustic detection of labeled stem cells in Vivo. ACS Nano. doi: 10.1021/acsnano.6b03246 (2016).

  26. 26.

    Taruttis, A., Morscher, S., Burton, N. C., Razansky, D. & Ntziachristos, V. Fast multispectral optoacoustic tomography (MSOT) for dynamic imaging of pharmacokinetics and biodistribution in multiple organs. PLoS One. doi:10.1371/journal.pone.0030491 (2012).

  27. 27.

    McNally, L. R. et al. Current and emerging clinical applications of multispectral optoacoustic tomography (MSOT) in oncology. Clin. Cancer Res. 22, 3432–3439 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Taruttis, A. et al. Optoacoustic imaging of human vasculature: feasibility by using a handheld probe. Radiology 281, 256–263 (2016).

    PubMed  Article  Google Scholar 

  29. 29.

    Waldner, M. J. et al. Multispectral optoacoustic tomography in crohn’s disease: noninvasive imaging of disease activity. Gastroenterology 151, 238–240 (2016).

    PubMed  Article  Google Scholar 

  30. 30.

    Comenge, J. et al. Preventing plasmon coupling between gold nanorods improves the sensitivity of photoacoustic detection of labeled stem cells in vivo. ACS nano 10, 7106–7116 (2016).

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Kraitchman, D. L. & Bulte, J. W. In vivo imaging of stem cells and Beta cells using direct cell labeling and reporter gene methods. Arterioscler. Thromb. Vasc. Biol. 29, 1025–1030 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Zhou, B. et al. MR tracking of SPIO-labeled mesenchymal stem cells in rats with liver fibrosis could not monitor the cells accurately. Contrast Media Mol. Imaging 10, 473–480 (2015).

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Ottobrini, L., Martelli, C., Trabattoni, D. L., Clerici, M. & Lucignani, G. In vivo imaging of immune cell trafficking in cancer. Eur. J. Nucl. Med. Mol. Imaging 38, 949–968 (2011).

    PubMed  Article  Google Scholar 

  34. 34.

    Bouabe, H., Fassler, R. & Heesemann, J. Improvement of reporter activity by IRES-mediated polycistronic reporter system. Nucleic Acids Res. 36, e28 (2008).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  35. 35.

    Yaghoubi, S. S., Campbell, D. O., Radu, C. G. & Czernin, J. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications. Theranostics 2, 374–391 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Lyons, S. K., Patrick, P. S. & Brindle, K. M. Imaging mouse cancer models in vivo using reporter transgenes. Cold Spring Harbor Protoc. 2013, 685–699 (2013).

    Article  Google Scholar 

  37. 37.

    Tennstaedt, A. et al. Human neural stem cell intracerebral grafts show spontaneous early neuronal differentiation after several weeks. Biomaterials 44, 143–154 (2015).

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Tang, Y. et al. In vivo tracking of neural progenitor cell migration to glioblastomas. Hum. Gene Ther. 14, 1247–1254 (2003).

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Rabinovich, B. A. et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc. Natl. Acad. Sci. USA 105, 14342–14346 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Katsuoka, Y. et al. Intra-arterial catheter system to repeatedly deliver mesenchymal stem cells in a rat renal failure model. Clin. Exp. Nephrol. 20, 169–177 (2016).

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Sharkey, J. et al. Imaging technologies for monitoring the safety, efficacy and mechanisms of action of cell-based regenerative medicine therapies in models of kidney disease. Eur. J. Pharmacol. 790, 74–82 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Heslop, J. A. et al. Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl. Med. 4, 389–400 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Wang, L. V. & Hu, S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science 335, 1458–1462 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Nam, S. Y., Ricles, L. M., Suggs, L. J. & Emelianov, S. Y. In vivo ultrasound and photoacoustic monitoring of mesenchymal stem cells labeled with gold nanotracers. PLoS One 7, e37267 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Terrovitis, J. et al. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J. Am. Coll. Cardiol. 54, 1619–1626 (2009).

    PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Gholamrezanezhad, A. et al. In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl. Med. Biol. 38, 961–967 (2011).

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Sato, N. et al. (89)Zr-oxine complex PET Cell imaging in monitoring cell-based therapies. Radiology 275, 490–500 (2015).

    PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Perin, E. C. et al. Imaging long-term fate of intramyocardially implanted mesenchymal stem cells in a porcine myocardial infarction model. PLoS One 6, e22949 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Keu, K. V. et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Science translational medicine. doi:10.1126/scitranslmed.aag2196 (2017).

  50. 50.

    Ponomarev, V. et al. A human-derived reporter gene for noninvasive imaging in humans: mitochondrial thymidine kinase type 2. J. Nucl. Med. 48, 819–826 (2007).

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Chen, I. Y. et al. Micro-positron emission tomography imaging of cardiac gene expression in rats using bicistronic adenoviral vector-mediated gene delivery. Circulation 109, 1415–1420 (2004).

    PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Kim, Y. H. et al. Reversing the silencing of reporter sodium/iodide symporter transgene for stem cell tracking. J. Nucl. Med. 46, 305–311 (2005).

    CAS  PubMed  Google Scholar 

  53. 53.

    Cao, F. et al. Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation. Cancer Res. 69, 2709–2713 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Patrick, P. S. et al. Dual-modality gene reporter for in vivo imaging. Proc. Natl. Acad. Sci. USA 111, 415–420 (2014).

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Patrick, P. S., Lyons, S. K., Rodrigues, T. B. & Brindle, K. M. Oatp1 enhances bioluminescence by acting as a plasma membrane transporter for D-luciferin. Mol. Imaging Biol. 16, 626–634 (2014).

    PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Ngen, E. J. et al. Imaging transplanted stem cells in real time using an MRI dual-contrast method. Sci. Rep. 5, 13628 (2015).

    PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Magnitsky, S. et al. In vivo and ex vivo MRI detection of localized and disseminated neural stem cell grafts in the mouse brain. Neuroimage 26, 744–754 (2005).

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Goldring, C. E. et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell 8, 618–628 (2011).

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Song, W. K. et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Rep. 4, 860–872 (2015).

    CAS  Article  Google Scholar 

  60. 60.

    Zhang, T. et al. Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res. Ther. 4, 70 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Dobrovolskaia, M. A. & McNeil, S. E. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J. Control. Rel. 172, 456–466 (2013).

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Tang, C., Weissman, I. L. & Drukker, M. Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives. Methods Mol. Biol. (Clifton, N.J.) 1029, 17–31 (2013).

    CAS  Article  Google Scholar 

  63. 63.

    Copland, J. A. et al. Bioconjugated gold nanoparticles as a molecular based contrast agent: Implications for imaging of deep tumors using optoacoustic tomography. Molecular Imaging and Biology 6, 341–349 (2004).

    CAS  Article  Google Scholar 

  64. 64.

    Zakrzewski, J. L., van den Brink, M. R. M. & Hubbell, J. A. Overcoming immunological barriers in regenerative medicine. Nat Biotech. 32, 786–794 (2014).

    CAS  Article  Google Scholar 

  65. 65.

    Lund, R. J., Narva, E. & Lahesmaa, R. Genetic and epigenetic stability of human pluripotent stem cells. Nature reviews Genetics 13, 732–744 (2012).

    PubMed  Article  Google Scholar 

  66. 66.

    Eisenblatter, M. et al. In vivo optical imaging of cellular inflammatory response in granuloma formation using fluorescence-labeled macrophages. J. Nucl. Med. 50, 1676–1682 (2009).

    PubMed  Article  CAS  Google Scholar 

  67. 67.

    Youniss, F. M. et al. Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling. PLoS One 9, e109162 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  68. 68.

    Haney, M. J. et al. Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases. PLoS One 8, e61852 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Al Faraj, A., Sultana Shaik, A., Pureza, M. A., Alnafea, M. & Halwani, R. Preferential macrophage recruitment and polarization in LPS-induced animal model for COPD: noninvasive tracking using MRI. PLoS One 9, e90829 (2014).

    PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Ricles, L. M., Nam, S. Y., Treviño, E. A., Emelianov, S. Y. & Suggs, L. J. A dual gold nanoparticle system for mesenchymal stem cell tracking. J. Mater. Chem. B 2, 8220–8230 (2014).

    CAS  Article  Google Scholar 

  71. 71.

    Wax, A., Backman, V. Progress in Biomedical Optics and Imaging - Proceedings of SPIE: Introduction. Progress in Biomedical Optics and Imaging - Proceedings of SPIE, 6446 (2007).

  72. 72.

    Tillack, K., Aboutalebi, H. & Kramer, E. R. An efficient and versatile system for visualization and genetic modification of dopaminergic neurons in transgenic mice. PLoS One 10, e0136203 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  73. 73.

    Cao, J. et al. Animal model expressing luciferase under control of the myelin basic protein promoter (mbp-luci) and use of the model for bioluminescence in vivo imaging. Google patents (2016).

  74. 74.

    Ahn, B.-C. et al. Noninvasive reporter gene imaging of human Oct4 (Pluripotency) dynamics during the differentiation of embryonic stem cells in living subjects. Mol. Imaging Biol. 16, 865–876 (2014).

    PubMed  Article  Google Scholar 

  75. 75.

    Yang, J.-j. et al. Real-time tracking of adipose tissue-derived stem cells with injectable scaffolds in the infarcted heart. Heart Vessel. 28, 385–396 (2013).

    Article  Google Scholar 

  76. 76.

    Nam, S. Y., Ricles, L. M., Suggs, L. J. & Emelianov, S. Y. Imaging strategies for tissue engineering applications. Tissue Eng. Part B Rev. 21, 88–102 (2015).

    PubMed  Article  Google Scholar 

  77. 77.

    Scarfe, L. et al. Measures of kidney function by minimally invasive techniques correlate with histological glomerular damage in SCID mice with adriamycin-induced nephropathy. Sci. Rep. 5, 13601 (2015).

    PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Rich, L. J. & Seshadri, M. Photoacoustic imaging of vascular hemodynamics: validation with blood oxygenation level-dependent MR imaging. Radiology 275, 110–118 (2015).

    PubMed  Article  Google Scholar 

  79. 79.

    Nasiriavanaki, M. et al. High-resolution photoacoustic tomography of resting-state functional connectivity in the mouse brain. Proc. Natl. Acad. Sci. USA 111, 21–26 (2014).

    CAS  PubMed  Article  Google Scholar 

  80. 80.

    Pan, D. et al. Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. FASEB J. 25, 875–882 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  81. 81.

    Nam, S. Y., Chung, E., Suggs, L. J. & Emelianov, S. Y. Combined ultrasound and photoacoustic imaging to noninvasively assess burn injury and selectively monitor a regenerative tissue-engineered construct. Tissue Eng. Part C Methods 21, 557–566 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  82. 82.

    Freeman, B. J. et al. Allogeneic mesenchymal stem cells promote healing in postero-lateral annular lesions and improve indices of lumbar intervertebral disc degeneration in an ovine model. Spine (Phila Pa 1976). doi:10.1097/brs.0000000000001528 (2016).

  83. 83.

    Saeed, M., Van, T. A., Krug, R., Hetts, S. W. & Wilson, M. W. Cardiac MR imaging: current status and future direction. Cardiovasc. Diagn. Ther. 5, 290–310 (2015).

    PubMed  PubMed Central  Google Scholar 

  84. 84.

    Taouli, B., Ehman, R. L. & Reeder, S. B. Advanced MRI methods for assessment of chronic liver disease. Am. J. Roentgenol. 193, 14–27 (2009).

    Article  Google Scholar 

  85. 85.

    Nikken, J. J. & Krestin, G. P. MRI of the kidney-state of the art. Eur. Radiol. 17, 2780–2793 (2007).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  86. 86.

    Lehericy, S. et al. The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. Mov. Disord. 32, 510–525 (2017).

    PubMed  Article  Google Scholar 

  87. 87.

    Trattnig, S. et al. Magnetic resonance imaging of cartilage repair: a review. Cartilage 2, 5–26 (2011).

    PubMed  PubMed Central  Article  Google Scholar 

  88. 88.

    Geng, Y. et al. Mesenchymal stem cells ameliorate rhabdomyolysis-induced acute kidney injury via the activation of M2 macrophages. Stem Cell Res. Ther. 5, 80 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  89. 89.

    Santeramo, I. et al. Human kidney-derived cells ameliorate acute kidney injury without engrafting into renal tissue. Stem Cells Transl. Med. 2157–6564 (2017).

  90. 90.

    Li, Z. et al. Optimization of mesenchymal stem cells (MSCs) delivery dose and route in mice with acute liver injury by bioluminescence imaging. Mol. Imaging Biol. 17, 185–194 (2015).

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    European Medicines Agency (E.M.A.) guidelines. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003898.pdf (2009).

  92. 92.

    Tangney, M. & Francis, K. P. In vivo optical imaging in gene & cell therapy. Curr. Gene Ther. 12, 2–11 (2012).

    CAS  PubMed  Article  Google Scholar 

  93. 93.

    Afshari, A., Uhde-Stone, C. & Lu, B. A cooled CCD camera-based protocol provides an effective solution for in vitro monitoring of luciferase. Biochem. Biophys. Res. Commun. 458, 543–548 (2015).

    CAS  PubMed  Article  Google Scholar 

  94. 94.

    Moore, M. M. & Chung, T. Review of key concepts in magnetic resonance physics. Pediatr. Radiol. 47, 497–506 (2017).

    PubMed  Article  Google Scholar 

  95. 95.

    Zuckier, L. S. Principles and advanced methods in medical imaging and image analysis, Vol. 63 (Stallion Press, 2008).

  96. 96.

    Rahmim, A. & Zaidi, H. PET versus SPECT: strengths, limitations and challenges. Nucl. Med. Commun. 29, 193–207 (2008).

    PubMed  Article  Google Scholar 

  97. 97.

    Rodriguez-Porcel, M., Wu, J. C. & Gambhir, S. S. Molecular Imaging of Stem Cells. Harvard Stem Cell Institute. doi/10.3824/stembook.1.49.1 (2009).

  98. 98.

    Zeng, G. L., Galt, J. R., Wernick, M. N., Mintzer, R. A. & Aarsvold, J. N. Emission Tomography: The Fundamentals of PET and SPECT 127 (Elsevier Inc., 2004).

  99. 99.

    Yao, J. & Wang, L. V. Photoacoustic tomography: fundamentals, advances and prospects. Contrast Media Mol. Imaging 6, 332–345 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  100. 100.

    Niederhauser, J. J., Jaeger, M., Lemor, R., Weber, P. & Frenz, M. Combined ultrasound and optoacoustic system for real-time high-contrast vascular imaging in vivo. IEEE Trans. Med. Imaging 24, 436–440 (2005).

    PubMed  Article  Google Scholar 

  101. 101.

    Li, C. et al. Real-time photoacoustic tomography of cortical hemodynamics in small animals. J. Biomed. Opt. 15, 010509 (2010).

    PubMed  PubMed Central  Article  Google Scholar 

  102. 102.

    Buehler, A., Herzog, E., Razansky, D. & Ntziachristos, V. Video rate optoacoustic tomography of mouse kidney perfusion. Opt. Lett. 35, 2475–2477 (2010).

    PubMed  Article  Google Scholar 

  103. 103.

    Stoffels, I. et al. Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging. Sci. Transl. Med. 7, 317ra199 (2015).

    PubMed  Article  CAS  Google Scholar 

  104. 104.

    Ford, S. J. et al. Structural and functional analysis of intact hair follicles and pilosebaceous units by volumetric multispectral optoacoustic tomography. J. Invest. Dermatol. 136, 753–761 (2016).

    CAS  PubMed  Article  Google Scholar 

  105. 105.

    Needles, A. et al. Development and initial application of a fully integrated photoacoustic micro-ultrasound system. IEEE. Trans. Ultrason. Ferroelectr. Freq. Control 60, 888–897 (2013).

    PubMed  Article  Google Scholar 

  106. 106.

    Adam, V. Phototransformable fluorescent proteins: which one for which application? Histochem. Cell Biol. 142, 19–41 (2014).

    CAS  PubMed  Article  Google Scholar 

  107. 107.

    Accomasso, L., Gallina, C., Turinetto, V. & Giachino, C. Stem cell tracking with nanoparticles for regenerative medicine purposes: an overview. Stem Cells Int. doi:10.1155/2016/7920358 (2016).

  108. 108.

    Wu, S. Q., Chi, C. W., Yang, C. X. & Yan, X. P. Penetrating peptide-bioconjugated persistent nanophosphors for long-term tracking of adipose-derived stem cells with superior signal-to-noise ratio. Anal. Chem. 88, 4114–4121 (2016).

    CAS  PubMed  Article  Google Scholar 

  109. 109.

    Barrow, M., Taylor, A., Murray, P., Rosseinsky, M. J. & Adams, D. J. Design considerations for the synthesis of polymer coated iron oxide nanoparticles for stem cell labelling and tracking using MRI. Chem. Soc. Rev. 44, 6733–6748 (2015).

    CAS  PubMed  Article  Google Scholar 

  110. 110.

    Srivastava, A. K. et al. Advances in using MRI probes and sensors for in vivo cell tracking as applied to regenerative medicine. Dis. Models Mech. 8, 323–336 (2015).

    CAS  Article  Google Scholar 

  111. 111.

    Srinivas, M. et al. In vivo 19F MRI for cell tracking. J. Vis. Exp. doi:10.3791/50802 (2013).

  112. 112.

    Charoenphun, P. et al. [89Zr]Oxinate4 for long-term in vivo cell tracking by positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 42, 278–287 (2015).

    CAS  PubMed  Article  Google Scholar 

  113. 113.

    Rosado-De-Castro, P. H. et al. Radiopharmaceutical stem cell tracking for neurological diseases. BioMed Res. Int. doi:10.1155/2014/417091 (2014).

  114. 114.

    Li, W. & Chen, X. Gold nanoparticles for photoacoustic imaging. Nanomedicine 10, 299–320 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  115. 115.

    Close, D. M. et al. Autonomous bioluminescent expression of the bacterial luciferase gene cassette (lux) in a mammalian cell line. PLoS One 5, e12441 (2010).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  116. 116.

    Luker, K. E. et al. Comparative study reveals better far-red fluorescent protein for whole body imaging. Sci. Rep. 5, 10332 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  117. 117.

    Deliolanis, N. C. et al. Deep-tissue reporter-gene imaging with fluorescence and optoacoustic tomography: a performance overview. Mol. Imaging Biol. doi:10.1007/s11307-014-0728-1 (2014).

  118. 118.

    Paproski, R. J., Forbrich, A. E., Wachowicz, K., Hitt, M. M. & Zemp, R. J. Tyrosinase as a dual reporter gene for both photoacoustic and magnetic resonance imaging. Biomed. Opt. Express 2, 771–780 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  119. 119.

    Pereira, S. M., Moss, D., Williams, S. R., Murray, P. & Taylor, A. Overexpression of the MRI reporter genes ferritin and transferrin receptor affect iron homeostasis and produce limited contrast in mesenchymal stem cells. Int. J. Mol. Sci. 16, 15481–15496 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  120. 120.

    Blasberg, R. G. & Tjuvajev, J. G. Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q. J. Nucl. Med. Mol. Imaging 43, 163–169 (1999).

    CAS  Google Scholar 

  121. 121.

    Gambhir, S. S. et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2, 118–138 (2000).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  122. 122.

    MacLaren, D. C. et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene. Ther. 6, 785–791 (1999).

    CAS  PubMed  Article  Google Scholar 

  123. 123.

    Shin, J. H. et al. Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk. Eur. J. Nucl. Med. Mol. Imaging 31, 425–432 (2004).

    CAS  PubMed  Article  Google Scholar 

  124. 124.

    Buursma, A. R. et al. The human norepinephrine transporter in combination with 11C-m-hydroxyephedrine as a reporter gene/reporter probe for PET of gene therapy. J. Nucl. Med. 46, 2068–2075 (2005).

    CAS  PubMed  Google Scholar 

  125. 125.

    Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotech. 32, 347–355 (2014).

    CAS  Article  Google Scholar 

  126. 126.

    Sakudo, A. Near-infrared spectroscopy for medical applications: Current status and future perspectives. Clin. Chim. Acta 455, 181–188 (2016).

    CAS  PubMed  Article  Google Scholar 

  127. 127.

    Hajjar, R. J. & Cormode, D. P. Tracking cell therapy: bioluminescence lighting the way. JACC. Cardiovascular Imaging 5, 56–58 (2012).

  128. 128.

    Abramovitz, M. et al. Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform. British Journal of Cancer 105, 1574–1581 (2011).

  129. 129.

    Kirschner, S. et al. In vivo micro-CT imaging of untreated and irradiated orthotopic glioblastoma xenografts in mice: capabilities, limitations and a comparison with bioluminescence imaging. Journal of Neuro-Oncology 122, 245–254 (2015).

  130. 130.

    Pereira, S. M., Moss, D., Williams, S. R., Murray, P. & Taylor, A. Overexpression of the MRI Reporter Genes Ferritin and Transferrin Receptor Affect Iron Homeostasis and Produce Limited Contrast in Mesenchymal Stem Cells. International Journal of Molecular Sciences 16, 15481–15496 (2015).

  131. 131.

    O'Farrell, A. C., Shnyder, S. D., Marston, G., Coletta, P. L. & Gill, J. H. Non-invasive molecular imaging for preclinical cancer therapeutic development. British Journal of Pharmacology 169, 719–735 (2013).

  132. 132.

    Cunha, L. et al. Preclinical imaging: an essential ally in modern biosciences. Molecular Diagnosis & Therapy 18, 153–173 (2014).

  133. 133.

    Schmidt, G. P., Reiser, M. F. & Baur-Melnyk, A. Whole-body imaging of the musculoskeletal system: the value of MR imaging. Skeletal Radiology 36, 1109–1119 (2007).

  134. 134.

    Wang, C. et al. Protamine Functionalized Single-Walled Carbon Nanotubes for Stem Cell Labeling and In Vivo Raman/Magnetic Resonance/Photoacoustic Triple-Modal Imaging. Advanced Functional Materials 22, 2363–2375 (2012).

  135. 135.

    Jokerst, J. V., Thangaraj, M., Kempen, P. J., Sinclair, R. & Gambhir, S. S. Photoacoustic imaging of mesenchymal stem cells in living mice via silica-coated gold nanorods. ACS nano 6, 5920–5930 (2012).

  136. 136.

    Taruttis, A., Morscher, S., Burton, N. C., Razansky, D. & Ntziachristos, V. Fast multispectral optoacoustic tomography (MSOT) for dynamic imaging of pharmacokinetics and biodistribution in multiple organs. PloS one 7, e30491 (2012).

Download references

Acknowledgements

The authors would like to thank the organisers of the SafeSciMET workshop: ‘Drug Safety of Stem Cells and other Novel Therapeutics’, from which this review was an output. Imaging data was generated at the Centre for Preclinical Imaging (University of Liverpool), MRC Centre for Regenerative Medicine (University of Edinburgh), and Centre for Advanced Biomedical Imaging (University College London). The authors would also like to thank Michaela Sharpe, for valuable feedback on the content of the review. The review article was supported by the SafeSciMET programme, a European Community project under the Innovative Medicines Initiative Programme through Grant Agreement 115012. Additional support was provided by the UK Regenerative Medicine Platform (UKRMP) hub, ‘Safety and Efficacy, focussing on Imaging Technologies’ (joint funded by MRC, EPSRC, BBSRC; grant MR/K026739/1), and the MRC Centre for Drug Safety Science (CDSS) (grant G0700654).

Author information

Affiliations

Authors

Contributions

L.S., N.B., J.D.K., P.M., C.E.P.G.: conception and design; L.S., N.B., J.D.K., P.M., N.A., A.A., M.A., S.B., V.J., M.N., S.P., G.R., A.V.: manuscript writing; I.B., M.B., N.C.B., J.C., F.D., J.E., J.H., D.R.J., T.K., C.L., M.F.L., S.P., P.S.P., J.P., J.R., E.R., J.S., G.S., P.S.L., G.S., A.T., B.W., H.P.: other (workshop lecture and comments during write-up); N.S.F., C.H.: administrative support; P.M., C.E.P.G., B.K.P.: final approval of manuscript.

Corresponding author

Correspondence to Chris E. P. Goldring.

Ethics declarations

Competing interests

The authors declare that they have no competing financial interests.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Scarfe, L., Brillant, N., Kumar, J.D. et al. Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies. npj Regen Med 2, 28 (2017). https://doi.org/10.1038/s41536-017-0029-9

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing